[1] Wilkins T, Sams R, Carpenter M. Hepatitis B: screening, prevention, diagnosis, and treatment[J]. Am Fam Physician, 2019, 99(5):314-323.
[2] Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy[J]. Clin Microbiol Rev, 2020, 33(2):e00046-19.
[3] Sinha P, Thio CL, Balagopal A. Intracellular host restriction of hepatitis B virus replication[J]. Viruses, 2024, 16(5):764.
[4] Dilcan KH, Gozdas HT. Noninvasive evaluation of significant liver fibrosis in chronic hepatitis B patients[J]. Acta Gastroenterol Belg, 2024, 87(3):388-392.
[5] Wu D, Liu Z, Song Z, et al. A novel chronic hepatitis B mouse model with immune activation and liver fibrosis[J]. Microbiol Spectr, 2025, 13(9):e0251324.
[6] Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer[J].Clin Sci (Lond), 2022, 136(3):197-222.
[7] Wang L, Zhao XP, Xie JJ, et al. The roles of Hippo-YAP/TAZ and Notch signaling pathways in liver fibrosis [J]. Chemistry of Life, 2023, 43(3):402-407. (in Chinese)
王莉, 赵秀萍, 谢娇娇, 等. Hippo-YAP/TAZ与Notch信号通路在肝纤维化中的作用[J].生命的化学, 2023, 43(3):402-407.
[8] Driskill JH, Pan D. The hippo pathway in liver homeostasis and pathophysiology[J]. Annu Rev Pathol, 2021, 16:299-322.
[9] Yang MH, Ran HQ, Wang HB, et al. Effects of Wogonin on liver fibrosis in cirrhotic rats by regulating the Hippo/YAP signaling pathway[J]. Journal of Hunan University of Chinese Medicine, 2024, 44(7):1160-1166. (in Chinese)
杨茂辉, 冉恒泉, 王何斌, 等. 汉黄芩素调节Hippo/YAP信号通路对肝硬化大鼠肝纤维化的影响[J]. 湖南中医药大学学报, 2024, 44(7):1160-1166.
[10] Qu YN, Xin XL, Zhou HJ. Wogonin reduces the degree of fibrosis in cirrhotic rats by regulating Hedgehog-YAP signal pathway[J]. Chinese Journal of Anatomy, 2024, 47(1):35-39, 80. (in Chinese)
瞿旖妮, 辛晓丽, 周慧君. 汉黄芩素通过调节Hedgehog-YAP信号通路减轻肝硬化大鼠的肝纤维化[J]. 解剖学杂志, 2024, 47(1):35-39, 80.
[11] Wang Y, Wang LZh, Wang YD, et al. Influence of asiaticoside on liver fibrosis in hepatitis B model rats by inhibiting TGF-β1/Smad signaling pathway[J]. Infectious Disease Information, 2022, 35(6):496-501. (in Chinese)
汪燕, 王立志, 王运东, 等. 积雪草苷抑制TGF-β1/Smad信号通路对乙型肝炎模型大鼠肝纤维化的影响[J]. 传染病信息, 2022, 35(6):496-501.
[12] Zhou X, Wang H, Li D, et al. MST1/2 inhibitor XMU-MP-1 alleviates the injury induced by ionizing radiation in haematopoietic and intestinal system[J]. J Cell Mol Med, 2022, 26(5):1621-1628.
[13] Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3):230-238.
[14] Luo RL, Li SQ, Feng JY, et al. Effects and mechanisms of exogenous thyroid hormone t3 on liver oxidative stress in mice with alcoholic liver fibrosis[J]. Acta Anatomica Sinica, 2024, 55(6):753-760. (in Chinese)
罗仁利, 李三强, 冯家阳, 等. 外源性甲状腺激素T3对酒精性肝纤维化小鼠肝脏氧化应激的影响及其机制[J]. 解剖学报, 2024, 55(6):753-760.
[15] Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65:37-55.
[16] Yu X, Gao Y, Zhang X, et al. Hepatitis B: model systems and therapeutic approaches[J]. J Immunol Res, 2024, 2024:4722047.
[17] Spyrou E, Smith CI, Ghany MG. Hepatitis B: current status of therapy and future therapies[J].Gastroenterol Clin North Am, 2020, 49(2):215-238.
[18] Sharifi-Rad J, Herrera-Bravo J, Salazar LA, et al. The therapeutic potential of wogonin observed in preclinical studies[J]. Evid Based Complement Alternat Med, 2021, 2021:9935451.
[19] He X, Wang J, Sun L, et al. Wogonin attenuates inflammation and oxidative stress in lipopolysaccharide-induced mastitis by inhibiting Akt/NF-κB pathway and activating the Nrf2/HO-1 signaling[J]. Cell Stress Chaperones, 2023, 28(6):989-999.
[20] Yamada Y, Saito H, Araki M, et al. Wogonin, a compound in scutellaria baicalensis, activates ATF4-FGF21 signaling in mouse hepatocyte AML12 cells[J]. Nutrients, 2022, 14(19):3920.
[21] Naderi M, Salavatiha Z, Gogoi U, et al. An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action[J]. Front Cell Infect Microbiol, 2024, 14:1356003.
[22] Liu Y, Wang X, Yang Y. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma[J]. Clin Mol Hepatol, 2020, 26(4):742-750.
[23] Moon H, Cho K, Shin S, et al. High risk of hepatocellular carcinoma development in fibrotic liver: role of the Hippo-YAP/TAZ signaling pathway[J]. Int J Mol Sci, 2019, 20(3):581.
[24] Nishina H. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis[J]. Cancer Sci, 2022, 113(6):1900-1908.